Lorus Therapeutics Presents At The 10th International Congress On Anti-Cancer Treatment.Business Editors TORONTO--(BUSINESS WIRE)--Feb. 5, 2001 Company to Discuss Anti-Cancer Products At International Conference in France Lorus Therapeutics Inc. ("Lorus") (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :LORFF)(TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :LOR LOR Letter Of Reprimand (military) LoR Lord of the Rings (J.R.R. Tolkien) LOR Learning Object Repository LOR Linux.Org. .) announced today that Dr. Guy Ely, vice-president clinical and medical affairs, and Geoff Collett, vice-president, corporate development, will present information about the company's most advanced anti-cancer products at the 10th International Congress on Anti-Cancer Treatment ("ICACT") in Paris, France, February 6th to 9th, 2001. Lorus will report on the progress of its anti-cancer products from a business and a clinical development perspective and will feature Lorus' promising novel anti-cancer drugs and therapies, Virulizin(R) and antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). products GTI-2040 and GTI-2501. Specifically, Lorus will outline its plans to begin a Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the for Virulizin(R) in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. and to initiate a Phase I clinical study for GTI-2501 in the U.S. The status of the GTI-2040 Phase I/II clinical trial and its advancement into a multiple Phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II program will also be discussed. "Presenting at ICACT, a prestigious European conference, is an opportunity for Lorus to showcase its promising drug development programs and strategies to an influential audience from the international oncology community. This event also enables Lorus to explore and develop potential synergies between our company and physicians, scientists, pharmaceutical companies and commercial partners," said Dr. Jim A. Wright, president of Lorus. ICACT is one of the major international congresses dedicated to advancing the treatment of cancer and will be attended by approximately eight thousand professionals from around the world. The conference is organized by the Service d'Oncologie Medicale Pitie Salpetiere (SOMPS) and the University of Texas M.D. Anderson Cancer Center (MDACC MDACC M D Anderson Cancer Center (Houston, Texas) MDACC Management of Defense Acquisition Contracts Course ). About Lorus Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. under the symbol LOR, and on the OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB exchange under the symbol LORFF. Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual reports and 40-F filings. Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: www.lorusthera.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion